The generic drug development timeline depends on a number of technical, regulatory, and manufacturing factors, so it can vary from one product to another. The generic drug development process usually includes reference product evaluation, API and excipient studies, preformulation, formulation development, analytical method development, process development, scale-up, stability testing, and bioequivalence studies where required. The type and complexity of the dosage form also have an important effect on the timeline. The availability and quality of the API, difficulty in matching the reference product, formulation optimization, analytical testing, and stability requirements can also affect development time. In addition, regulatory requirements for the target market, preparation of the submission dossier, review questions, and any additional studies requested by the regulatory authority may extend the overall timeline. During generic product development, unexpected formulation or manufacturing issues may also require additional development batches and testing. Therefore, effective planning, early identification of technical challenges, and a well-defined regulatory strategy are important for keeping the development of generic drugs on track and supporting a smoother pharmaceutical generic product development process.